New drug MT-2990 tested in rare blood vessel disease
NCT ID NCT06196905
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study looked at a new drug, MT-2990, in 5 people with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. The goal was to see if the drug is safe and how it affects disease activity. Researchers measured changes in symptoms, imaging, and lab tests, but no single main outcome was set.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA) -ASSOCIATED VASCULITIS (AAV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hiroshima University Hospital
Hiroshima, Hiroshima, 734-8551, Japan
-
Juntendo University Hospital
Bunkyo-ku, Tokyo, 113-8431, Japan
-
Kagawa University Hospital
Kita-gun, Kagawa-ken, 761-0793, Japan
-
Keio University Hospital
Shinjuku-ku, Tokyo, 160-8582, Japan
-
Kyorin University Hospital
Mitaka-shi, Tokyo, 181-8611, Japan
-
NHO Tokyo Medical Center
Meguro-ku, Tokyo, 152-8902, Japan
-
Saitama Medical Center
Kawagoe, Saitama, 350-8550, Japan
-
Saitama Medical University Hospital
Iruma-gun, Saitama, 350-0495, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a diabetes drug shield kidneys from autoimmune attack?
- Promising vasculitis drug trial halted early
- Experimental liquid drug tested in ventilator patients with rare lung bleeding disease
- Hydroxychloroquine trial for rare vasculitis halted early
- New hope for Wegener's patients: drug aims to stop flare-ups
- New hope for rare vasculitis: Three-Drug trial targets Non-Responders